HK1054763B - 免疫毒素聚變蛋白質以及它們的表達方式 - Google Patents

免疫毒素聚變蛋白質以及它們的表達方式

Info

Publication number
HK1054763B
HK1054763B HK03106334.9A HK03106334A HK1054763B HK 1054763 B HK1054763 B HK 1054763B HK 03106334 A HK03106334 A HK 03106334A HK 1054763 B HK1054763 B HK 1054763B
Authority
HK
Hong Kong
Prior art keywords
expression
immunotoxin fusion
fusion proteins
abstract
immunotoxins
Prior art date
Application number
HK03106334.9A
Other languages
English (en)
Other versions
HK1054763A1 (en
Inventor
David M Neville Jr
Jerry T Thompson
Huaizhong Hu
Jung-Hee Woo
Shenglin Ma
Jonathan Mark Hexham
Mary Ellen Digan
Original Assignee
The Government Of The United States Of America Represented By The Dept Of Health & Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The United States Of America Represented By The Dept Of Health & Human Services filed Critical The Government Of The United States Of America Represented By The Dept Of Health & Human Services
Publication of HK1054763A1 publication Critical patent/HK1054763A1/xx
Publication of HK1054763B publication Critical patent/HK1054763B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK03106334.9A 2000-05-18 2003-09-05 免疫毒素聚變蛋白質以及它們的表達方式 HK1054763B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57379700A 2000-05-18 2000-05-18
PCT/US2001/016125 WO2001087982A2 (en) 2000-05-18 2001-05-18 Immunotoxin fusion proteins and means for expression thereof

Publications (2)

Publication Number Publication Date
HK1054763A1 HK1054763A1 (en) 2003-12-12
HK1054763B true HK1054763B (zh) 2010-10-22

Family

ID=24293426

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03106334.9A HK1054763B (zh) 2000-05-18 2003-09-05 免疫毒素聚變蛋白質以及它們的表達方式

Country Status (8)

Country Link
EP (1) EP1287147B1 (zh)
JP (1) JP4927291B2 (zh)
AT (1) ATE452196T1 (zh)
AU (2) AU6176001A (zh)
CA (2) CA2858692A1 (zh)
DE (1) DE60140802D1 (zh)
HK (1) HK1054763B (zh)
WO (1) WO2001087982A2 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
WO2003051926A2 (en) * 2001-12-14 2003-06-26 Friedrich-Alexander-Universitaet Erlangen-Nuernberg Anti-cd7 immunotoxin as fusion protein
EP1400534B1 (en) * 2002-09-10 2015-10-28 Affimed GmbH Human CD3-specific antibody with immunosuppressive properties
CN104356241A (zh) * 2003-08-01 2015-02-18 美国政府（由卫生和人类服务部、国立卫生研究院的部长所代表） 免疫毒素的表达和纯化方法
JP2009502205A (ja) * 2005-08-02 2009-01-29 プラネット・バイオテクノロジー・インコーポレイテッド 炭疽菌の処置および予防のための改良されたキメラ毒素受容体タンパクおよびキメラ毒素受容体タンパク質
FR2897069B1 (fr) 2006-02-08 2012-06-08 Centre Nat Rech Scient Construction de nouveaux variants de l'enzyme dextrane-saccharase dsr-s par ingienerie moleculaire.
CA2695382A1 (en) 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health Of Human Services, National Institutes Of A fold-back diabody diphtheria toxin immunotoxin and methods of use
AU2008321026B2 (en) * 2007-11-13 2014-01-16 The Scripps Research Institute Production of cytotoxic antibody-toxin fusion in eukaryotic algae
US9321820B2 (en) * 2009-10-14 2016-04-26 The Regents Of The University Of Colorado Compositions and methods for treating bladder cancer
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
CN103173429A (zh) * 2013-03-11 2013-06-26 江南大学 一种热稳定性提高的重组胰蛋白酶
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
WO2018031507A1 (en) * 2016-08-09 2018-02-15 Angimmune, Llc Treatment of cancer using a combination of immunomodulation and check point inhibitors
WO2019149219A1 (zh) * 2018-02-05 2019-08-08 思路迪（北京）医药科技有限公司 抗-cd3免疫毒素联合抗-pd-l1单域抗体治疗癌症的应用
EP3851112A4 (en) * 2018-09-14 2022-07-27 Luca Science Inc. TRANSPLANTATION OF MITOCHONDRIA IN A LYMPHOID ORGAN AND ASSOCIATED COMPOSITION

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0830146B1 (en) * 1995-04-14 2010-03-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods of inducing immune tolerance using immunotoxins
ATE433998T1 (de) * 1997-03-05 2009-07-15 Us Health Divalent anti-t-zellen immuntoxinen und deren verwendung
CA2283497A1 (en) * 1997-03-05 1998-09-11 David M. Neville Vectors and methods for expression of mutant proteins

Also Published As

Publication number Publication date
CA2858692A1 (en) 2001-11-22
AU6176001A (en) 2001-11-26
ATE452196T1 (de) 2010-01-15
JP2003533219A (ja) 2003-11-11
DE60140802D1 (de) 2010-01-28
WO2001087982A3 (en) 2002-03-21
EP1287147B1 (en) 2009-12-16
HK1054763A1 (en) 2003-12-12
CA2409746C (en) 2014-11-25
AU2001261760B2 (en) 2007-03-29
CA2409746A1 (en) 2001-11-22
JP4927291B2 (ja) 2012-05-09
WO2001087982A2 (en) 2001-11-22
EP1287147A2 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
AU6176001A (en) Immunotoxin fusion proteins and means for expression thereof
MXPA04005266A (es) Inmunocitocinas con selectividad modulada.
CA2063427A1 (en) Rapid, versatile and simple system for expressing genes in eukaryotic cells
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
WO2001058957A3 (en) Enhancing the circulating half-life of antibody-based fusion proteins
ATE544776T1 (de) Chimäre dna-bindeproteine
WO2002024930A3 (en) Artificial ubiquitous chromatin opening elements (ucoe)
WO2000017364A3 (en) Cyclin d polynucleotides, polypeptides and uses thereof
EP0783527A4 (en) PROTEASE CATHEPSINE O2
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
DE60144145D1 (de) Subtilisin-variante
IL139478A0 (en) Hybrid protein
HK1065335A1 (en) Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture
WO2000016407A3 (de) Geschaltetes netzteil mit reduzierten schaltverlusten
IL148505A0 (en) Progressive additions lenses
CA2160131A1 (en) New Bacillus Thuringiensis Strains and Their Insecticidal Proteins
IL136668A0 (en) Restin and methods of use thereof
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
AU2003213580A1 (en) Subtilisin carlsberg proteins with reduced immunogenicity
AU3477295A (en) Modified proteins
WO2002036627A3 (en) Interferons, uses and compositions related thereto
AU2002217721A1 (en) Viral vector for gene therapy
WO2003045429A3 (en) Anti-t cell immunotoxin fusion protein and its therapeutic use
MXPA03007713A (es) Metodos para elaborar un oxido de metal de niobio.
AU2002345213A1 (en) Expression vectors encoding bacteriophage signal peptides

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20210517